<DOC>
	<DOCNO>NCT01819389</DOCNO>
	<brief_summary>The purpose study determine low-dose imatinib nilotinib combination , improve treatment result CML patient failure , suboptimal response intolerance imatinib therapy . The hypothesis low-dose imatinib nilotinib combination , major molecular response achieve patient previously obtain imatinib monotherapy .</brief_summary>
	<brief_title>Low-dose Nilotinib Imatinib Combination Chronic Myeloid Leukemia Patients , With Failure , Suboptimal Response Treatment Intolerance</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>CML patient failure suboptimal response imatinib therapy accord criterion establish European Leukemia Net ( ELN ) Patients grade II high adverse event . CML patient suitable stem cell transplantation . Patients blast crisis . Pregnant woman Patients without contraception method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>suboptimal response</keyword>
	<keyword>imatinib</keyword>
	<keyword>nilotinib</keyword>
</DOC>